COVID, Pneumonia, Viral
Conditions
Keywords
covid-19 pneumonia, Low dose Radiotherapy
Brief summary
The administration of low-dose lung irradiation produces anti-inflammatory effects that will decrease the pulmonary inflammatory response. The present study will evaluate the efficacy of treatment with low-dose pulmonary radiotherapy added to standard support therapy, in hospitalized patients with respiratory symptoms due to COVID-19 pneumonia, who do not experience improvement with conventional medical therapy and are not subsidiaries of ICU
Detailed description
The WHO has officially confirmed that: Currently, there is no specific pharmacological available treatment for COVID-19. Beyond vital support, there are not currently treatment options for Coronavirus disease (COVID-19) and related pneumonia, the infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Pulmonary irradiation is an option for the treatment of COVID-19 pneumonia and could be available quickly and with a duration of about 15 minutes of treatment. Thoracic irradiation therapy at very low doses (0.5-1.0 Gy) dates back to the 1920s and was the only effective mean to treat certain infectious and inflammatory diseases prior to the development of antimicrobial therapies in the 1940s. The goal is to replicate low-dose radiation therapy, just as it was used 80 years ago for viral pneumonia with great success. It will be administered for a new disease, pneumonia caused by COVID-19, for which there is no cure and many people are dying, mainly from severe acute respiratory syndrome leading to very severe hypoxemic acute respiratory failure refractory to treatment. This therapy is expected to remedy acute respiratory syndrome by reducing inflammation, and it also has a low risk of side effects and toxicities, given the low doses received, more than one hundred times lower, compared to the usual radiotherapy used to tumor treatment.
Interventions
RADIATIONLung Low Dose Radiation
The administration of low-dose lung radiation produces anti-inflammatory effects that will decrease the pulmonary inflammatory response.
Sponsors
Hospital Provincial de Castellon
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients over 65 years old * Hospitalized with COVID-19 positive not subsidiary of ICU with severe disease defined by the presence of ALL the following characteristics: * Presence of unilateral or bilateral pulmonary infiltrates in chest X-ray or computed tomography (CT). * Acute respiratory failure expressed by PaO2 / FIO2 \<300. * Lymphopenia ≤0.8 × 109 / L (800 lymphocytes / ml). * Patients with ≤8 days from the onset of symptoms.
Exclusion criteria
* Patient not consent to participate
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| blood oxygen saturation level | 48 hours | Clinical improvement of respiratory symptoms due to COVID-19 pneumonia after the treatment, measured as blood oxygen saturation levels |
| Torax X-ray | 48 hours | radiological improvement of respiratory symptoms due to COVID-19 pneumonia after the treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hospitalization | 2 months | number of days of hospital stay. |
| days free of assisted mechanical respiration | 3 month | Number of days free of assisted mechanical respiration. |
| Mortality | 3 months | number of deaths |
Countries
Spain
Contacts
Primary ContactFrancisco Garcia Piñón, MSc
Outcome results
None listed